BCG vaccine prevents insulitis in low dose streptozotocin-induced diabetic mice

Diabetes Research and Clinical Practice

Volumn 46, Issue 2, 1999, Pages 91-97

  Baik, Sei Hyun ^a   Park, Ie Byung ^a   Choi, Kyung Mook ^a   Kim, Yong Hyun ^a   Kim, Nan Hee ^a   Kim, Sang Jin ^a   Song, Gwan Gyu ^a   Choi, Dong Seop ^a  

^a Kyung Hee University   (South Korea)

Author keywords

Autoimmune type 1 diabetes mellitus; BCG; Insulitis; LDSD

Indexed keywords

BCG VACCINE; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BCG VACCINATION; BODY WEIGHT; CONTROLLED STUDY; DISEASE SEVERITY; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; MOUSE; NONHUMAN;

ANIMALS; BCG VACCINE; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DOSE-RESPONSE RELATIONSHIP, DRUG; ISLETS OF LANGERHANS; MICE; MICE, INBRED STRAINS; STREPTOZOCIN;

EID: 0344069775     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(99)00079-0     Document Type: Article

References (36)

1. Edward H.L., Beamer W.G., Shultz L.D. The effect of immunosuppression on streptozotocin-induced diabetes in C57BL/KsJ mice. Diabetes. 32:1983;148-155.
2. Anderson T., Schein P.S., McMenamin M.G., Cooney D.A. Streptozotocin diabetes: correlation with extent of depression of pancreatic islet nicotinamide adenine dinucleotide. J. Clin. Invest. 54:1974;672-677.
3. Vialettes B., Picq R., Rostu M.D., Chabonnel B., Rodier M., Mirouze J., Vexiau P., Passa P., Pehuet M., Elgrably F., Vague P. A preliminary multicentre study of the treatment of recently diagnosed type 1 diabetes by combination nicotinamide-cyclosporin therapy. Diabetic Med. 7:1990;731-735.
4. Lazalus S.S., Shapiro S.H. Influence of nicotinamide and pyridine nucleotides on streptozotocin and alloxan induced pancreatic B cell cytotoxicity. Diabetes. 22:1973;409-506.
5. Ledoux S.P., Hall C.R., Forbes P.M., Patton N.J., Wilson G.L. Mechanisms of nicotinamide and thymidine protection from alloxan and streptozotocin toxicity. Diabetes. 37:1988;1015-1019.
6. Mendola J., Wright J.R., Lacy P.E. Oxygen free radical scavengers and immune destruction of murine islets in allograft rejection of multiple low dose streptozotocin-induced insulitis. Diabetes. 38:1989;379-385.
7. Herskowitz R.D., Jackson R.A., Soeldner J.S., Eisenbarth G.S. Pilot trial to prevent type I diabetes: progression to overt IDDM despite oral nicotinamide. J. Autoimmun. 2:1989;733-737.
8. Vague P., Picq R., Bernal M., Vague V.L., Vialettes B. Effect of nicotinamide treatment on the residual insulin secretion in type 1 (insulin-dependent) diabetes patients. Diabetologia. 32:1989;316-321.
9. Rossini A.A., Williams R.M., Appel M.C., Like A.A. Complete protection from low dose streptozotocin-induced diabetes in mice. Nature. 276:1978;182-184.
10. Nomikos I.N., Proowse S.J., Carotenuto P., Laffery K.J. Combined treatment with nicotinamide and desferrioxamine prevents islet allograft destruction in NOD mice. Diabetes. 35:1986;1302-1304.
11. Kentaro Y., Kyohei N., Toshiaki H., Atsushi M., Hiroyuki T., Seichiro T. Preventive and therapeutic effects of large-dose nicotinamide injections on diabetes associated with insulitis: An observation in nonobese diabetic (NOD) mice. Diabetes. 31:1982;749-753.
12. .Pozzilli P., Visalli N., Ghirlanda G., Manna R., Andrani D. Nicotinamide increase C-peptide secretion in patients with recent onset type 1 diabetes. Diabetic Med. 6:1989;568-572.
13. Chase H.P., Simon N.B., Garg S., McDuffie M., Hoops S.L., Brien D.O. A trial of nicotinamide in newly diagnosed patients with type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 33:1990;444-446.
14. Like A.A., Rossini A.A. Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus. Science. 193:1976;415-417.
15. Kolb H. Mouse model of insulin dependent diabetes: low dose streptozotocin-induced diabetes and nonobese diabetic (NOD) mice. Diabetes/Metabol. Rev. 3:1987;751-771.
16. Edward H.L., Beamer W.G., Schultz L.D. The effect of immunosuppression on streptozotocin - in diabetes in C57BL/KsJ mice. Diabetes. 32:1983;148-155.
17. Wright J.R., Haliburton B., Henry H., Fraser R., Cook H.W. The anti-diabetogenic effect of essenrial fatty acid deficiency in multiple low dose streptozotocin treated mice persists in essential fatty acid repletion occurs outside of a brief window of susceptibility. Diabetologia. 34:1991;709-714.
18. Rabinovitch A. Immunoregulatory and cytokine imbalances in the pathogenesis of IDDM - therapeutic intervention by immunostimulation? Diabetes. 43:1994;613-621.
19. Bredt D.S., Hwang P.M., Snyder S.H. Localization of nitric oxide synthetase indicating a neural role for nitric oxide. Nature. 347:1990;768-770.
20. Jhonstone M.T., Creager S.J., Scales K.M., Cusco J.A., Lee B.K., Creager M.A. Impaired endothelium dependent vasodilation in patients with insulin dependent diabetes mellitus. Circulation. 88:1993;2510-2516.
21. Nggrd Erik Nitric oxide:mediator, murderer, and medicine. Lancet. 343:1994;1199-1206.
22. Kolb H., Kiesel U., Kroncke K.D., Bachofen V.K. Suppression of low dose streptozotocin induced diabetes in mice by administration of a nitric oxide synthetase inhibitor. Life Sci. 49:1991;213-217.
23. Fehsel K., Jalowy A., Qi S., Burkart V., Hartmann B., Kolb H. Islet cell DNA is a target of inflammatory attack by nitric oxide. Diabetes. 42:1993;496-500.
24. Corbett J.A., Tilton R.G., Chang K., Hansan K.S., Ido Y., Wang J.L., Sweetland M.A., Lancaster J.R., Williamson J.R., McDaniel M.L. Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes. 41:1992;552-556.
25. Corbett J.A., McDaniel M.L. Does nitric oxide mediate autoimmune destruction of ß-cells?: possible therapeutic interventions in IDDM. Diabetes. 41:1992;897-903.
26. Eisenbarth G., Verge C.F., Allen H., Rewers M.J. The design of trials for prevention of IDDM. Diabetes. 42:1993;941-947.
27. Brudzinski K., Martinez V., Gupta R.S. Immunocytochemical localization of heat-shock protein 60-related protein in beta-cell secretory granules and its altered distribution in nonobese diabetic mice. Diabetologia. 35:1992;316-324.
28. Corbett J.A., Michael A., Shimizu J., Frederick K., Misko T.P., McDaniel M.L., Kanakawa O., Unanue E.R. Nitric oxide production in islets from nonobese diabeticmice: aminoguanidine sensitive and resistant stages in the immunological diabetic process. Immunology. 90:1993;8992-8995.
29. Wang T., Singh B., Warnock G.L., Rajotte R.V. Prevention of recurrence of IDDM in islet transplantated diabetic NOD mice by adjuvant immunotherapy. Diabetes. 41:1992;114-117.
30. Lee K.U. Nitric oxide produced by macrophages mediates supression of conA-induced proliferative responses of splenic leukocytes in the diabetes prone BB rat. Diabetes. 43:1994;1218-1220.
31. Elias D., Prigozin H., Polak N., Rapoport M., Lohse A.W., Cohen I.R. Autoimmune diabetes induced by the β-cell toxin STZ. Diabetes. 43:1994;992-998.
32. Mcinerney M.F., Pek S.B., Thomas D.W. Prevention of insulitis and diabetes onset by treatment with Complete Freund's Adjuvant in NOD mice. Diabetes. 40:1991;715-725.
33. Andersen H.U., Jrgensen K.H., Egeberg J., Poulsen T.M., Nerup J. Nicotinamide prevents interleukin-1 effects on accumlated insulin release and nitric oxide production in rat islets of langerhans. Diabetes. 43:1994;770-777.
34. Elias D., Cohen I.R. Peptide therapy for diabetes in NOD mice. Lancet. 343:1994;704-706.
35. Shehadeh N., Calcinaro F., Bradley B.J., Bruchlim I., Vardi P., Laffferty K.J. Effect of adjuvant therapy on development of diabetes in mouse and men. Lancet. 343:1994;706-707.
36. Elliott J.F., Marlin K.L., Couch R.M. Effect of Bacille Calmette-Guerin vaccination on c-peptide secretion in children newly diagnosed with IDDM. Diabetes Care. 21:1998;1691-1693.